Anti-Spike SARS-CoV-2 IgG Assessment with a Commercial Assay during a 4-Month Course after COVID-19 Vaccination

We intended to assess the humoral response induced by the Pfizer/BioNTech Comirnaty COVID-19 vaccine with commercially available immunoassays: anti-spike (S) IgG and IgM, and anti-nucleocapsid (N) IgG antibodies, over a 4-month course. One hundred subjects, including 15 COVID-19 convalescents, compr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jakub Swadźba, Tomasz Anyszek, Andrzej Panek, Emilia Martin
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	SARS-CoV-2 antibodies COVID-19 testing COVID-19 vaccines COVID-19 vaccines booster shot Medicine R
Acceso en línea:	https://doaj.org/article/81d9d99ff95c4f208db17f815b29de2e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:81d9d99ff95c4f208db17f815b29de2e
record_format	dspace
spelling	oai:doaj.org-article:81d9d99ff95c4f208db17f815b29de2e2021-11-25T19:11:41ZAnti-Spike SARS-CoV-2 IgG Assessment with a Commercial Assay during a 4-Month Course after COVID-19 Vaccination10.3390/vaccines91113672076-393Xhttps://doaj.org/article/81d9d99ff95c4f208db17f815b29de2e2021-11-01T00:00:00Zhttps://www.mdpi.com/2076-393X/9/11/1367https://doaj.org/toc/2076-393XWe intended to assess the humoral response induced by the Pfizer/BioNTech Comirnaty COVID-19 vaccine with commercially available immunoassays: anti-spike (S) IgG and IgM, and anti-nucleocapsid (N) IgG antibodies, over a 4-month course. One hundred subjects, including 15 COVID-19 convalescents, comprised the study cohort. The SARS-CoV-2 antibodies concentrations were measured on day 0′ and 10′, 20′, 30′, 60′, 90′, and 120′ after the first dose administration. Over the course of the study, 100% of the participants developed and sustained anti-SARS-CoV-2 S IgG antibodies. The highest concentration, exceeding the quantification range of the test (2080 BAU/mL), was reached by 67% of the subjects on day 30′. The concentration of the antibodies remained stable between days 30′ and 90′ but was followed by a significant decrease between days 90′ and 120′. The stronger and more persistent humoral response was noted for women. The COVID-19 convalescents developed higher antibody levels, particularly 10 days after the first Comirnaty dose. Twenty-three out of the eighty-five naïve vaccinees failed to develop a detectable IgM response. LIAISON<sup>®</sup> SARS-CoV-2 TrimericS IgG (DiaSorin S.p.A, Saluggia, Italy) may be useful in the assessment of the humoral response to the Comirnaty vaccine. In contrast, Abbott’s anti-S SARS-CoV-2 IgM has a limited utility in this context.Jakub SwadźbaTomasz AnyszekAndrzej PanekEmilia MartinMDPI AGarticleSARS-CoV-2 antibodiesCOVID-19 testingCOVID-19 vaccinesCOVID-19 vaccines booster shotMedicineRENVaccines, Vol 9, Iss 1367, p 1367 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	SARS-CoV-2 antibodies COVID-19 testing COVID-19 vaccines COVID-19 vaccines booster shot Medicine R
spellingShingle	SARS-CoV-2 antibodies COVID-19 testing COVID-19 vaccines COVID-19 vaccines booster shot Medicine R Jakub Swadźba Tomasz Anyszek Andrzej Panek Emilia Martin Anti-Spike SARS-CoV-2 IgG Assessment with a Commercial Assay during a 4-Month Course after COVID-19 Vaccination
description	We intended to assess the humoral response induced by the Pfizer/BioNTech Comirnaty COVID-19 vaccine with commercially available immunoassays: anti-spike (S) IgG and IgM, and anti-nucleocapsid (N) IgG antibodies, over a 4-month course. One hundred subjects, including 15 COVID-19 convalescents, comprised the study cohort. The SARS-CoV-2 antibodies concentrations were measured on day 0′ and 10′, 20′, 30′, 60′, 90′, and 120′ after the first dose administration. Over the course of the study, 100% of the participants developed and sustained anti-SARS-CoV-2 S IgG antibodies. The highest concentration, exceeding the quantification range of the test (2080 BAU/mL), was reached by 67% of the subjects on day 30′. The concentration of the antibodies remained stable between days 30′ and 90′ but was followed by a significant decrease between days 90′ and 120′. The stronger and more persistent humoral response was noted for women. The COVID-19 convalescents developed higher antibody levels, particularly 10 days after the first Comirnaty dose. Twenty-three out of the eighty-five naïve vaccinees failed to develop a detectable IgM response. LIAISON<sup>®</sup> SARS-CoV-2 TrimericS IgG (DiaSorin S.p.A, Saluggia, Italy) may be useful in the assessment of the humoral response to the Comirnaty vaccine. In contrast, Abbott’s anti-S SARS-CoV-2 IgM has a limited utility in this context.
format	article
author	Jakub Swadźba Tomasz Anyszek Andrzej Panek Emilia Martin
author_facet	Jakub Swadźba Tomasz Anyszek Andrzej Panek Emilia Martin
author_sort	Jakub Swadźba
title	Anti-Spike SARS-CoV-2 IgG Assessment with a Commercial Assay during a 4-Month Course after COVID-19 Vaccination
title_short	Anti-Spike SARS-CoV-2 IgG Assessment with a Commercial Assay during a 4-Month Course after COVID-19 Vaccination
title_full	Anti-Spike SARS-CoV-2 IgG Assessment with a Commercial Assay during a 4-Month Course after COVID-19 Vaccination
title_fullStr	Anti-Spike SARS-CoV-2 IgG Assessment with a Commercial Assay during a 4-Month Course after COVID-19 Vaccination
title_full_unstemmed	Anti-Spike SARS-CoV-2 IgG Assessment with a Commercial Assay during a 4-Month Course after COVID-19 Vaccination
title_sort	anti-spike sars-cov-2 igg assessment with a commercial assay during a 4-month course after covid-19 vaccination
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/81d9d99ff95c4f208db17f815b29de2e
work_keys_str_mv	AT jakubswadzba antispikesarscov2iggassessmentwithacommercialassayduringa4monthcourseaftercovid19vaccination AT tomaszanyszek antispikesarscov2iggassessmentwithacommercialassayduringa4monthcourseaftercovid19vaccination AT andrzejpanek antispikesarscov2iggassessmentwithacommercialassayduringa4monthcourseaftercovid19vaccination AT emiliamartin antispikesarscov2iggassessmentwithacommercialassayduringa4monthcourseaftercovid19vaccination
_version_	1718410167285972992

Anti-Spike SARS-CoV-2 IgG Assessment with a Commercial Assay during a 4-Month Course after COVID-19 Vaccination

Ejemplares similares